Copy Link Print Information

Favipiravir sodium

(Synonyms: T-705 sodium)
51 Cited Publications
Customer Review

Based on 51 publication(s) in Google Scholar

Favipiravir (T-705) sodium is an inhibitor of viral RNA polymerase (RNA polymerase), which is converted into its active form Favipiravir-ribofuranosyl-5′-triphosphate (RTP). Favipiravir-RTP inhibits the activity of influenza virus RNA-dependent RNA polymerase (RdRP) with an IC50 of 341 nM.

For research use only. We do not sell to patients.

  • CAS No.: 1366418-99-6
  • Formula: C5H3FN3NaO2
  • Molecular Weight:179.08
  • Storage:

    Please store the product under the recommended conditions in the Certificate of Analysis.

  • Favipiravir sodium Chemical Structure
    Favipiravir sodium Chemical Structure
  • Experimental Validation Results for Favipiravir sodium
  • Experimental Validation Results for Favipiravir sodium
  • Experimental Validation Results for Favipiravir sodium
  • Experimental Validation Results for Favipiravir sodium
  • Experimental Validation Results for Favipiravir sodium
  • Experimental Validation Results for Favipiravir sodium
CAS No.: 1366418-99-6
Size
Price
Stock
Quantity
Amount: USD 0.00
Please select quantity
or
or

* Please select Quantity before adding items.

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Data Download
Other Forms of Favipiravir sodium:

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
Find Your Local Distributor Your local distributor: Hycultec GmbHHycultec
  • Biological Activity
  • Chemical Information
  • Purity & Documentation
  • References
  • Help & FAQs
Top Publications Citing

Use of MCE Products

Publications Citing Use of MedChemExpress (MCE) Favipiravir sodium

More
Customer Validation & Images
Microbiological AssayOthersCell Proliferation/Viability AssayIF
  • Others
  • Microbiological Assay
  • Microbiological Assay
  • Cell Proliferation/Viability Assay
  • IF
  • IF

All DNA/RNA Synthesis Isoforms

More
Keywords
100 mg

Get Quote In-stock

Please select quantity
Amount: USD 0.00
Sign in to MedChemExpress Sign In
Register
Sign in to MedChemExpress
Register New Account

At least 6 characters

Personalize your experience, you are currently not signed in. For a better experience, please create an online profile, you can:

Obtain points redemption prizes
Check out faster
Add multiple shipping locations
View orders
Assay Types
  • Favipiravir sodium Chemical Structure
    Favipiravir sodium Chemical Structure
    1/16
  • 1/16

    Favipiravir sodium purchased from MedChemExpress. Usage Cited in: Emerg Microbes Infect. 2025 Dec;14(1):2564308. [Abstract]

    Customer Validation
     Drug susceptibility profiles of Favipiravir were assessed using a viral yield reduction assay in MDCK cells. Cells were infected with IDV and IAV (MOI = 0.1), followed by removal of the virus inoculum and treatment with the drugs. Supernatants from IDV and Influenza A virus (IAV) infections were collected at 72 and 48 hpi, respectively, and viral titres were determined in MDCK cells. Antiviral activity (%) was calculated relative to virus-free and drug-free controls.

  • 1/16

    Favipiravir sodium purchased from MedChemExpress. Usage Cited in: Front Pharmacol. 2019 Oct 16;10:1203. [Abstract]

    Customer Validation
     Vero E6 cells in 12-well plates were infected with HTNV at an FFU of 30/well (T-705; Favipiravir) and incubated with a CMC overlay supplemented with serial two-fold dilutions of inhibitors. At 5 dpi, the foci were counted and calculated. These experiments were performed independently at least three times with similar results.

  • 1/16

    Favipiravir sodium purchased from MedChemExpress. Usage Cited in: Front Pharmacol. 2019 Oct 16;10:1203. [Abstract]

    Customer Validation
     Inhibitory effects of T-705 (Favipiravir) and BXA (Baloxavir) on HTNV replication, as measured by FFA. Vero E6 cells were infected with HTNV at an FFU of 30/well (T-705) or 50/well (BXA) and treated with serial two-fold dilutions of inhibitors. The foci were counted 5 dpi. Each point represents the mean and SD of three independent experiments.

  • 1/16

    Favipiravir sodium purchased from MedChemExpress. Usage Cited in: Front Pharmacol. 2019 Oct 16;10:1203. [Abstract]

    Customer Validation
     Cell viability as a percentage of the control cell (treated with DMSO for T-705 or PBS for BXA) viability in uninfected Vero E6 cells incubated for 72 h post-T-705 (Favipiravir)/BXA (Baloxavir) treatment. Each point represents the mean and SD of three independent experiments.

  • 1/16

    Favipiravir sodium purchased from MedChemExpress. Usage Cited in: BMC Vet Res. 2019 Sep 2;15(1):316. [Abstract]

    Customer Validation
     Comparisons of antiviral effects of T-705 and anti-CDV polyclonal serum. The Vero and DH82 cells were treated with T-705 (156.25 μg/ml), anti-CDV polyclonal serum (1:128) and a combination of T-705 (156.25 μg/ml) and anti-CDV polyclonal serum (1:128) at 0, 12, 24, 36 and 48 h p.i. with CDV-3 and CDV-11 at a MOI of 0.1. The mock groups were treated with DMEM p.i. at the same times. Viral replications in cells were detected by IFA and the mean fluorescence percentages (a, c, e, g) were calculated

  • 1/16

    Favipiravir sodium purchased from MedChemExpress. Usage Cited in: BMC Vet Res. 2019 Sep 2;15(1):316. [Abstract]

    Customer Validation
     Comparisons of antiviral effects of T-705 and anti-CDV polyclonal serum. The Vero and DH82 cells were treated with T-705 (156.25 μg/ml), anti-CDV polyclonal serum (1:128) and a combination of T-705 (156.25 μg/ml) and anti-CDV polyclonal serum (1:128) at 0, 12, 24, 36 and 48 h p.i. with CDV-3 and CDV-11 at a MOI of 0.1. The mock groups were treated with DMEM p.i. at the same times. The virus titers in supernatant (b, d, f, h) were determined and compared with the viral titers in mock group. All e

  • Favipiravir sodium